ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0834

Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry

Stefano Fiore1, Lang Chen2, Cassie Clinton2, Huifeng Yun2, Amy Praestgaard3, Kerri Ford3 and Jeffrey R Curtis2, 1Sanofi, Bridgewater, NJ, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Sanofi, Cambridge, MA

Meeting: ACR Convergence 2020

Keywords: comparative effectiveness, Disease Activity, Interleukins, registry, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may lead to worse clinical response to treatment. We examined characteristics of sarilumab-treated patients with RA in order to evaluate the hypothesis that disease severity was greater in those who received sarilumab shortly after its Food and Drug Administration (FDA) approval (May 2017) than in subsequent time periods.

Methods: Patients with RA who initiated sarilumab treatment from May 2017 to June 2019 were identified in the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness (RISE) registry. They were divided into 3 cohorts based on time since FDA approval, with the overall period divided into tertiles rounded to the nearest calendar quarter (Cohort 1: May 2017 to March 2018; Cohort 2: April 2018 to December 2018; Cohort 3: January 2019 to June 2019). Patient characteristics reflecting demographics, RA-related features, and comorbidities (measured based on prescriptions, using the RxRisk score) were evaluated using all available data prior to sarilumab initiation. Between-cohort comparisons were made using chi-square test for categorical variables and a nonparametric test for continuous variables.

Results: A total of 2039 patients, treated by 585 rheumatologists, initiated sarilumab treatment in the period May 2017–June 2019 (Figure). Cohort comparison showed relative similarity over the 3 time periods in terms of patients’ age, sex, race, and most clinical characteristics (Table). However, patients receiving sarilumab shortly after FDA approval (Cohort 1) had more ambulatory visits, a greater number of previously used non-TNF inhibitor (TNFi) biologics (particularly tocilizumab), a higher comorbidity burden, and were more likely to be current users of glucocorticoids or opioids than patients in Cohorts 2 and 3. Ongoing work is evaluating comparative response to therapy in the 3 cohorts.

Conclusion: We observed modest evidence for channeling of patients with greater RA severity and greater prior exposure to non-TNFi biologics to a newly introduced biologic, although disease activity at time of initiation was comparable over the 3 time periods. For real-world evidence generation, considerations should include cohort effects related to the timing of new drug approval in order to make valid inferences resulting from comparative effectiveness research.

Figure 1

Table 1


Disclosure: S. Fiore, Sanofi, 1, 3; L. Chen, None; C. Clinton, None; H. Yun, Pfizer, 2; A. Praestgaard, Sanofi, 3; K. Ford, Sanofi Genzyme, 1, 2; J. Curtis, AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Myriad, 2, 5, Pfizer, 2, 5, Regeneron, 2, 5, Roche, 2, 5, UCB, 2, 5, Gilead Sciences, Inc., 5, Sanofi, 5.

To cite this abstract in AMA style:

Fiore S, Chen L, Clinton C, Yun H, Praestgaard A, Ford K, Curtis J. Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/is-disease-severity-greater-among-patients-with-rheumatoid-arthritis-who-receive-a-newly-approved-biologic-real-world-us-experience-with-sarilumab-from-the-acr-rise-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-disease-severity-greater-among-patients-with-rheumatoid-arthritis-who-receive-a-newly-approved-biologic-real-world-us-experience-with-sarilumab-from-the-acr-rise-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology